StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$66.12+3.41 (+5.44%)

Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –

TG Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

TG Therapeutics's EV/EBITDA was 74.7× on Nov 11, 2026, against 50.9× a year earlier. Over the last 3 years it ranged from 34.4× to 167.3×, with a median of 60.7×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202674.7×+29.1
2025Dec 31, 202545.6×+8.7
2024Oct 31, 202436.9×–

More TG Therapeutics figures

See a number that looks wrong?